CStone Pharmaceuticals (HKG:2616)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 9.79B +202.0% |
| Revenue (ttm) | 221.89M -55.6% |
| Net Income | -413.21M |
| EPS | -0.32 |
| Shares Out | 1.47B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,868,507 |
| Average Volume | 10,859,559 |
| Open | 6.50 |
| Previous Close | 6.43 |
| Day's Range | 6.36 - 7.06 |
| 52-Week Range | 2.03 - 13.15 |
| Beta | 0.61 |
| RSI | 60.20 |
| Earnings Date | Mar 26, 2026 |
About CStone Pharmaceuticals
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor... [Read more]
Financial Performance
In 2024, CStone Pharmaceuticals's revenue was 407.21 million, a decrease of -12.21% compared to the previous year's 463.84 million. Losses were -91.21 million, -75.16% less than in 2023.
Financial numbers in CNY Financial StatementsNews
CStone Secures MHRA Approval For Sugemalimab In Stage III NSCLC In UK
(RTTNews) - CStone Pharmaceuticals (CSPHF, 2616.HK) announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a new indication for sugemalimab as a monotherapy. This...
CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small ce...